Stifel Initiates Altimmune(ALT.US) With Buy Rating, Announces Target Price $18

Futu News07:31 · Ratings

Innovative Breakthrough in Metabolic Disease Treatment: Annabel Samimy's Buy Rating on Altimmune's Pemvidutide

TipRanks05:25

FDA Issues Draft Guidance on Developing Weight Loss Drugs

Seeking Alpha00:53

Institutional Owners May Consider Drastic Measures as Altimmune, Inc.'s (NASDAQ:ALT) Recent US$56m Drop Adds to Long-term Losses

Simply Wall StJan 2 18:56

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Jim Cramer on Altimmune, Inc. (ALT): 'Healthcare Is So Out Of Fashion'

Yahoo FinanceDec 29, 2024 04:39